Som.Ax

SOM.AX has a current ratio of 1.51, indicating moderate liquidity, but its free cash flow is negative at -1.69 million AUD, suggesting cash flow constraints. The company's debt-to-equity ratio is 0.17, which is relatively low, but its operating cash flow of 7.78 million AUD is not sufficient to cover capital expenditures of 3.98 million AUD. The company's liquidity risk is assessed as medium, with key flags indicating that net cash is negative after subtracting total debt.

Profitability metrics for SOM.AX are weak, with a return on equity of -7.45% and a return on assets of -4.27%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of 3.46 million AUD and an operating loss of 763,870 AUD, indicating a challenging operating environment. Gross profit of 66.75 million AUD is a positive, but it is not translating into operating or net profitability.

SOM.AX's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits the company's ability to offset losses in one area with gains in another.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and net income suggest a need for operational improvements or cost reductions to achieve sustainable growth. The capital expenditure of 3.98 million AUD indicates ongoing investment, but the negative free cash flow suggests that these investments are not yet generating sufficient returns.

Risk factors for SOM.AX include medium liquidity risk and low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or investments without external financing. There is no indication of near-term dilution pressure, but the company's financial performance may necessitate additional capital in the future.

Recent events and filings for SOM.AX include analyst estimates with a mean price target of 0.99 AUD and a median price target of 0.99 AUD. The mean recommendation is 1.67, indicating a generally positive outlook from analysts, with one strong buy, two buy, and no hold ratings. No recent transcripts or filings are available to provide additional context on the company's strategic direction or operational performance.